Cytosorbents Crp (CTSO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytosorbents Crp (CTSO) has a cash flow conversion efficiency ratio of -0.530x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.16 Million) by net assets ($2.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cytosorbents Crp (CTSO) balance sheet quality index to measure how much of total assets are equity-financed.
Cytosorbents Crp - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Cytosorbents Crp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Cytosorbents Crp to evaluate the quality of earnings relative to operating cash generation.
Cytosorbents Crp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytosorbents Crp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Investors House
HE:INVEST
|
-0.089x |
|
Caldwell Partners International Inc
TO:CWL
|
-0.159x |
|
Green Plus Co. Ltd
KQ:186230
|
0.075x |
|
Macro Metals Ltd
AU:M4M
|
-0.384x |
|
Medhelp Care AB
ST:MEDHLP
|
0.163x |
|
Vunani Ltd
JSE:VUN
|
0.145x |
|
Synergy House Berhad
KLSE:0279
|
0.111x |
|
CervoMed Inc.
NASDAQ:CRVO
|
-0.755x |
Annual Cash Flow Conversion Efficiency for Cytosorbents Crp (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cytosorbents Crp from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Cytosorbents Crp (CTSO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.90 Million | $-12.38 Million | -2.097x | -61.41% |
| 2024-12-31 | $11.11 Million | $-14.43 Million | -1.299x | -39.62% |
| 2023-12-31 | $23.28 Million | $-21.66 Million | -0.930x | -16.57% |
| 2022-12-31 | $35.37 Million | $-28.23 Million | -0.798x | -256.62% |
| 2021-12-31 | $62.58 Million | $-14.01 Million | -0.224x | -215.84% |
| 2020-12-31 | $79.22 Million | $-5.61 Million | -0.071x | +98.55% |
| 2019-12-31 | $3.42 Million | $-16.76 Million | -4.903x | -666.00% |
| 2018-12-31 | $16.93 Million | $-10.84 Million | -0.640x | -1.68% |
| 2017-12-31 | $10.26 Million | $-6.46 Million | -0.630x | -104.43% |
| 2016-12-31 | $-474.09K | $-6.73 Million | 14.198x | +1393.96% |
| 2015-12-31 | $8.21 Million | $-9.01 Million | -1.097x | +34.72% |
| 2014-12-31 | $3.96 Million | $-6.66 Million | -1.681x | -787.19% |
| 2013-12-31 | $-14.27 Million | $-3.49 Million | 0.245x | -21.37% |
| 2012-12-31 | $-11.63 Million | $-3.62 Million | 0.311x | +102.59% |
| 2011-12-31 | $318.34K | $-3.83 Million | -12.026x | -335.25% |
| 2010-12-31 | $-484.58K | $-2.48 Million | 5.112x | +342.31% |
| 2009-12-31 | $1.27 Million | $-2.67 Million | -2.110x | -110.46% |
| 2008-12-31 | $2.36 Million | $-2.37 Million | -1.002x | -103.98% |
| 2007-12-31 | $-104.30K | $-2.63 Million | 25.196x | +2189.66% |
| 2006-12-31 | $2.36 Million | $-2.85 Million | -1.206x | -299.98% |
| 2005-12-31 | $-82.93K | $-50.00K | 0.603x | -27.65% |
| 2004-12-31 | $-60.00K | $-50.00K | 0.833x | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more